Tema Etfs LLC Raises Stock Position in Waters Corporation $WAT

Tema Etfs LLC increased its stake in shares of Waters Corporation (NYSE:WAT) by 44.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,380 shares of the medical instruments supplier’s stock after purchasing an additional 1,356 shares during the period. Tema Etfs LLC’s holdings in Waters were worth $1,313,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. IFP Advisors Inc grew its stake in shares of Waters by 65.4% during the second quarter. IFP Advisors Inc now owns 134 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 53 shares in the last quarter. CYBER HORNET ETFs LLC bought a new position in Waters during the 2nd quarter worth approximately $53,000. MUFG Securities EMEA plc acquired a new position in shares of Waters in the 2nd quarter worth approximately $61,000. Creative Financial Designs Inc. ADV increased its stake in Waters by 533.3% during the second quarter. Creative Financial Designs Inc. ADV now owns 190 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 160 shares during the last quarter. Finally, Steph & Co. bought a new stake in Waters during the second quarter valued at $73,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on WAT. TD Cowen upped their price objective on Waters from $345.00 to $390.00 and gave the stock a “hold” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price target on shares of Waters from $300.00 to $325.00 and gave the stock a “neutral” rating in a research report on Thursday, October 9th. Morgan Stanley assumed coverage on shares of Waters in a research note on Monday, December 1st. They set an “equal weight” rating and a $423.00 price objective on the stock. Redburn Partners set a $390.00 price objective on Waters in a report on Wednesday, October 8th. Finally, Rothschild Redb raised shares of Waters to a “strong-buy” rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Waters has a consensus rating of “Moderate Buy” and a consensus price target of $395.00.

Waters Stock Performance

Shares of WAT stock opened at $393.87 on Tuesday. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $423.56. The stock’s 50-day moving average is $387.62 and its two-hundred day moving average is $339.24. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.08. The firm has a market cap of $23.46 billion, a P/E ratio of 36.20, a PEG ratio of 3.32 and a beta of 1.16.

Waters (NYSE:WAT) last released its quarterly earnings results on Thursday, May 19th. The medical instruments supplier reported $2.29 earnings per share for the quarter. Waters had a net margin of 20.89% and a return on equity of 36.59%. The business had revenue of $608.55 million for the quarter. Waters has set its FY 2025 guidance at 13.050-13.150 EPS and its Q4 2025 guidance at 4.450-4.550 EPS. Analysts predict that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.